The goal of the trial is to determine whether human albumin, administered within 5 hours of
symptom onset, improves the 3-month outcome of subjects with acute ischemic stroke.
Phase:
Phase 3
Details
Lead Sponsor:
University of Miami
Collaborators:
Medical University of South Carolina National Institute of Neurological Disorders and Stroke (NINDS) Neurological Emergencies Treatment Trials Network (NETT) University of Calgary